These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8606326)

  • 1. Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients.
    Mann RD; Kubota K; Pearce G; Wilton L
    J Clin Epidemiol; 1996 Feb; 49(2):247-50. PubMed ID: 8606326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age- and gender-specific asthma death rates in patients taking long-acting beta2-agonists: prescription event monitoring pharmacosurveillance studies.
    Martin RM; Shakir S
    Drug Saf; 2001; 24(6):475-81. PubMed ID: 11368253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK.
    Meier CR; Jick H
    Thorax; 1997 Jul; 52(7):612-7. PubMed ID: 9246132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of prescription event monitoring study of salmeterol.
    Mann RD
    BMJ; 1994 Oct; 309(6960):1018. PubMed ID: 7950701
    [No Abstract]   [Full Text] [Related]  

  • 5. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment.
    Castle W; Fuller R; Hall J; Palmer J
    BMJ; 1993 Apr; 306(6884):1034-7. PubMed ID: 8098238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects on resource utilization of adding salmeterol in combination or separately to inhaled corticosteroids.
    Chan J; Hui RL; Spence MM
    J Manag Care Pharm; 2007; 13(1):21-7. PubMed ID: 17269833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A modified prescription-event monitoring study to assess the introduction of Seretide Evohaler in England: an example of studying risk monitoring in pharmacovigilance.
    Perrio MJ; Wilton LV; Shakir SA
    Drug Saf; 2007; 30(8):681-95. PubMed ID: 17696581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events.
    Cates CJ; Lasserson TJ; Jaeschke R
    Cochrane Database Syst Rev; 2009 Jul; (3):CD006922. PubMed ID: 19588410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salmeterol: a novel, long-acting beta 2-agonist.
    Meyer JM; Wenzel CL; Kradjan WA
    Ann Pharmacother; 1993 Dec; 27(12):1478-87. PubMed ID: 7905757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
    D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI
    JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness.
    Rosenthal RR; Busse WW; Kemp JP; Baker JW; Kalberg C; Emmett A; Rickard KA
    Chest; 1999 Sep; 116(3):595-602. PubMed ID: 10492259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.
    Nelson HS; Weiss ST; Bleecker ER; Yancey SW; Dorinsky PM;
    Chest; 2006 Jan; 129(1):15-26. PubMed ID: 16424409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma.
    Busse W; Nelson H; Wolfe J; Kalberg C; Yancey SW; Rickard KA
    J Allergy Clin Immunol; 1999 Jun; 103(6):1075-80. PubMed ID: 10359889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events.
    Cates CJ; Lasserson TJ
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007695. PubMed ID: 19821436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 1-week dose-ranging study of inhaled salmeterol in patients with asthma.
    Bronsky EA; Kemp JP; Orgel HA; Bierman CW; Tinkelman DG; van As A; Liddle RF
    Chest; 1994 Apr; 105(4):1032-7. PubMed ID: 7909285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety, and impact on quality of life of salmeterol in patients with moderate persistent asthma.
    Busse WW; Casale TB; Murray JJ; Petrocella V; Cox F; Rickard K
    Am J Manag Care; 1998 Nov; 4(11):1579-87. PubMed ID: 10338904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma.
    Roberts JA; Bradding P; Britten KM; Walls AF; Wilson S; Gratziou C; Holgate ST; Howarth PH
    Eur Respir J; 1999 Aug; 14(2):275-82. PubMed ID: 10515401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events.
    Bateman E; Nelson H; Bousquet J; Kral K; Sutton L; Ortega H; Yancey S
    Ann Intern Med; 2008 Jul; 149(1):33-42. PubMed ID: 18523132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salmeterol/fluticasone propionate combination.
    Spencer CM; Jarvis B
    Drugs; 1999 Jun; 57(6):933-40; discussion 941-3. PubMed ID: 10400406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists.
    Martin RM; Dunn NR; Freemantle SN; Mann RD
    Thorax; 1998 Jul; 53(7):558-62. PubMed ID: 9797754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.